ABX203 is a therapeutic vaccine composed of 2 recombinant proteins from HBV.

ABIVAX doses first patient in ABX203 Stage IIb/III trial for treatment of chronic hepatitis B ABIVAX, a clinical stage biotech firm developing and commercialising anti-viral compounds and human vaccines, today announced that it provides dosed in New Zealand the first individual in a Stage IIb/III clinical trial of ABX203 which is occurring in a number of countries of the Asia-Pacific region info . The analysis is designed to assess whether ABX203 can deliver a significant improvement in the treatment of persistent hepatitis B via controlling viral load for a much longer period of period when compared to current treatment plans.

Leaders in the field and those with questions should feel absolve to convey their curiosity to the emerging AIHM's executive director, Nancy Sudak, MD, in. Leave comments regarding this announcement beneath the press tab at.. ABIHM expands to be the Academy of Integrative Wellness & Medicine In 2014, the American Board of Integrative Holistic Medicine will expand to be an international academy, the Academy of Integrative Wellness & Medicine . The mission of the extended global academy is to implement the science of health and curing into practice by getting leaders of medicine and the curing arts collectively into an academic and clinically concentrated community. In December 2013, stakeholders representing key businesses in the integrative health and medicine sector fulfilled formally in NORTH PARK to discuss the advancement of the academy, its major goals, and vision.